



Role of Matrix Metalloproteinase in Diseases

Guest Editor:

Prof. Dr. Shinji Takai

Department of Innovative
Medicine, Graduate School of
Medicine, Osaka Medical College,
Takatsuki, Japan

Deadline for manuscript
submissions:

closed (31 August 2022)

Message from the Guest Editor

Matrix metalloproteinases are enzymes that degrade the extracellular matrix, including collagen, elastin, and fibronectin, and their enzymatic actions are deeply involved in promoting the infiltration of inflammatory cells and the progression of fibrosis. Augmentation of these enzymes has been observed in various diseases, including vascular, heart, lung, liver, and kidney diseases, and the inhibition of these enzymes is expected to prevent and treat various diseases. Matrix metalloproteinases are expressed as their proforms which are activated by enzymes such as elastase and chymase, and the enhancement or inhibition of process also plays an important role in the regulation of matrix metalloproteinases, resulting in the involvement of various diseases. In this Special Issue, we are looking for a wide range of matrix metalloproteinase-related diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)